Stock LFMD LIFEMD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
9.32 USD +0.22% Intraday chart for LifeMD, Inc. -25.50% +12.42%
May. 09 Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating MT
May. 08 Transcript : LifeMD, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
LIFEMD, INC. Stock LifeMD, Inc.
+12.42% 381M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+5.85% 32.93B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+20.16% 7.94B
C-
SECTRA AB Stock Sectra AB
+30.81% 4.19B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-25.95% 2.8B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-19.96% 1.38B
B
LUNIT INC. Stock Lunit Inc.
-31.87% 1.17B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+8.02% 966M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-35.73% 900M -
VERADIGM INC. Stock Veradigm Inc.
-25.74% 839M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LFMD Stock
  4. Ratings LifeMD, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW